To print: Select File and then Print from your browser's menu

Title: Continuous Infusion Oxaliplatin/5-Fluorouracil/Leucovorin Active In Advanced Gastric Cancer

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12598342&dopt=Abstract

Annals of Oncology Mar 2003;14:383-387. "Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer."
03/07/2003 09:31:40 AM
By Elda Hauschildt

Oxaliplatin, 5-flourouracil plus leucovorin continuous infusion shows activity in advanced gastric cancer patients previously treated with 5-fluorouracil/platinum. Toxicities are acceptable, indicate results from a Phase II study at the Cancer Research Institute at Seoul National University College of Medicine in Seoul, Korea. Oxaliplatin shows pre-clinical activity in many cancer cell lines that are resistant to cisplatin, the researchers explain, and the drug has synergism with 5-flurouracil. They, therefore, evaluated the efficacy and toxicities of the combination in 26 patients with advanced gastric cancer. Participants had disease progression during or after chemotherapy with a 5-fluorouracil/platinum regimen. Combined therapy included oxaliplatin as a 2-hour infusion, followed by bolus 5-fluorouracil and 48-hour infusion of 5-fluorouracil concurrent with leucovorin. The cycles were repeated at 2-week intervals. Twenty three patients could be evaluated. Partial response was observed in 6 (26%). All of the responding patients entered the trial immediately after failing previous chemotherapy with 5-fluorouracil/cisplatin, the researchers point out. Median time to progression was 4.3 months. Median overall survival was 7.3 months. Grade1/2 anaemia, observed in 39 cycles (39%), was the most common haematological toxicity seen. The most common non-haematological toxicity was nausea/vomiting (33%). Grade 1 or grade 2 peripheral neuropathy was also observed in 27% of participants.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12598342&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.